Jo Varshney, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
A drug development approach that makes use of hybrid AI can de-risk drug development while simultaneously removing other barriers to success. In other words, it has the power to significantly reduce the drug development timeline, and ultimately, save more lives.
In a fireside chat at INVEST Digital Health in Dallas, Polsinelli Healthcare M&A Co-chair Jonathan Henderson and Jim Walton, President of JWalton LLC discussed the healthcare preferences of different generations and how they will impact caregiving.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.